

in any federal health care program any individual who has been convicted of a criminal offense “related to the delivery of an item or service under [42 U.S.C. 1395 *et seq.*] or under any State health care program.” The Agency has long held that the underlying conviction forming the basis for a registrant’s mandatory exclusion from participation in federal health care programs need not involve controlled substances for the Agency to revoke a DEA registration pursuant to § 824(a)(5). *E.g.*, *Orlando Ortega-Ortiz, M.D.*, 70 FR 15122, 15123 (2005); *Juan Pillot-Costas, M.D.*, 69 FR 62084, 62085 (2004); *Daniel Ortiz-Vargas, M.D.*, 69 FR 62095, 62095–62096 (2004); *KK Pharmacy*, 64 FR 49507, 49510 (1999); *Stanley Dubin, D.D.S.*, 61 FR 60727, 60728 (1996); *Nelson Ramirez-Gonzalez, M.D.*, 58 FR 52787, 52788 (1993).

Here, Registrant was convicted of two counts of felony Health Care Fraud related to billing for services that were not rendered. The Agency has previously held that a mandatory exclusion based on a felony fraud conviction for overbilling warranted revocation of a Registrant’s registration pursuant to 21 U.S.C. 824(a)(5). *E.g.*, *Johnnie Melvin Turner, M.D.*, 67 FR 71203, 71203–71204 (2002) (revocation where mandatory exclusion was based on guilty plea to one felony count of mail fraud “by billing for services that were not rendered”); *Dubin*, 61 FR at 60728 (revocation where mandatory exclusion “based upon fraudulent billing”); *Ramirez-Gonzalez*, 58 FR at 52788 (revocation where mandatory exclusion based on submission of false claims). Moreover, Registrant has failed to come forward with any evidence explaining or mitigating his overbilling conduct or otherwise explaining why his registration should not be revoked, and the record reflects no such evidence. *See Joseph M. Piacentile, M.D.*, 62 FR 35527, 35528 (1997) (revoking DEA registration where Registrant “did not offer any evidence into the record regarding why his registration should not be revoked” pursuant to § 824(a)(5)).

Based on the 2017 HHS letter, I find that the evidence shows that HHS excluded Registrant from participation in any federal health care program based on his federal convictions for health care fraud related to overbilling. Registrant has thus been excluded pursuant to the mandatory exclusion provisions of 42 U.S.C. 1320a–7(a), and I hold that this unchallenged basis for his mandatory exclusion is sufficient to warrant revocation of his DEA registration pursuant to 21 U.S.C. 824(a)(5).

Accordingly, I will order that his registration be revoked and deny any pending applications to renew or to modify his registration, as requested in the Show Cause Order. Order to Show Cause, at 1. Finally, because Registrant’s DATA-Waiver authority is contingent on Registrant being a practitioner with a valid DEA registration, *see* 21 U.S.C. 823(g)(2)(A); 21 CFR 1301.28(a), I will revoke his DATA-Waiver authority as well.

Order

Pursuant to the authority vested in me by 21 U.S.C. 823(f) and 824(a), as well as 28 CFR 0.100(b), I order that DEA Certificate of Registration No. BH2140692 and DATA-Waiver Identification Number XH2140692, issued to Richard Hauser, M.D., be, and they hereby are, revoked. I further order that any pending application of Richard Hauser to renew or to modify the above registration, be, and it hereby is, denied. This Order is effective July 6, 2018.

Dated: May 25, 2018.

Robert W. Patterson,

Acting Administrator.

[FR Doc. 2018–12138 Filed 6–5–18; 8:45 am]

BILLING CODE 4410–09–P

NEIGHBORHOOD REINVESTMENT CORPORATION

Annual Board of Directors Meeting; Sunshine Act

TIME AND DATE: 9:00 a.m., Wednesday, June 20, 2018.

PLACE: NonProfit HR, 1400 Eye Street NW, Suite 500, Washington, DC 20005.

STATUS: Open (with the exception of Executive Sessions).

CONTACT PERSON: Rutledge Simmons, Acting EVP & General Counsel/ Secretary, (202) 760–4105; *RSimmons@nw.org*.

Agenda

- I. Call to Order
- II. Approval of Minutes
- III. Report from Interim CEO
- IV. Board Elections
- V. Executive Session: Internal Audit Report
- VI. Adjournment

The General Counsel of the Corporation has certified that in his opinion, one or more of the exemptions set forth in 5 U.S.C. 552(b)(2) and (4) permit closure of the following portion(s) of this meeting:

- Report from CEO

- Internal Audit Report

Rutledge Simmons,

Acting EVP & General Counsel/Corporate Secretary.

[FR Doc. 2018–12309 Filed 6–4–18; 4:15 pm]

BILLING CODE 7570–02–P

NUCLEAR REGULATORY COMMISSION

[Docket No. 50–458; NRC–2017–0141]

Entergy Operations, Inc.; River Bend Station, Unit 1

AGENCY: Nuclear Regulatory Commission.

ACTION: Draft supplemental environmental impact statement; request for comment.

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) is issuing for public comment a draft plant-specific Supplement 58 to the Generic Environmental Impact Statement (GEIS) for License Renewal of Nuclear Plants, NUREG–1437, regarding the renewal of operating license NPF–47 for an additional 20 years of operation for River Bend Station (RBS), Unit 1. The RBS is located in West Feliciana Parish, Louisiana. Possible alternatives to the proposed action (license renewal) include no action and reasonable alternative energy sources.

DATES: Submit comments by July 23, 2018. Comments received after this date will be considered, if it is practical to do so, but the NRC staff is able to ensure consideration only for comments received on or before this date.

ADDRESSES: You may submit comments by any of the following methods:

- *Federal Rulemaking website:* Go to <http://www.regulations.gov> and search for Docket ID NRC–2017–0141. Address questions about NRC dockets to Jennifer Borges; telephone: 301 287–9127; *Jennifer.Borges@nrc.gov*. For technical questions, contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

- *Mail comments to:* May Ma, Chief, Office of Administration, Mail Stop: TWFN–7–A60M, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001.

For additional direction on obtaining information and submitting comments, see “Obtaining Information and Submitting Comments” in the **SUPPLEMENTARY INFORMATION** section of this document.

FOR FURTHER INFORMATION CONTACT: David Drucker, Office of Nuclear Reactor Regulation, U.S. Nuclear